Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma

Michael E. Wechsler, David Finn, Dineli Gunawardena, Robert Westlake, Alan Barker, Sai P. Haranath, Romain A. Pauwels, Johan C. Kips, Jeffrey M. Drazen

Research output: Contribution to journalArticle

210 Citations (Scopus)

Abstract

Study objectives: We previously reported eight patients who developed Churg-Strauss syndrome in association with zafirlukast treatment for asthma and postulated that the syndrome resulted from unmasking of a previously existing condition due to corticosteroid withdrawal and not from a direct drug effect. The availability of montelukast, a new leukotriene receptor antagonist with a different molecular structure, permitted us to test this hypothesis. Our goals were to ascertain whether the Churg-Strauss syndrome developed in patients taking montelukast and other novel asthma medications, and to describe potential mechanisms for the syndrome. Design: Case series. Setting: Outpatient and hospital practices of pulmonologists in the United States and Belgium. Patients: Four adults (one man, three women) who received montelukast as treatment for asthma; two women who received salmeterol/fluticasone therapy, but not montelukast. Results: Churg-Strauss syndrome developed in the four asthmatic patients who received montelukast. In each case, there was a long history of difficult-to-control asthma characterized by multiple exacerbations that had required frequent courses of oral systemic corticosteroids or high doses of inhaled corticosteroids for control. Two other asthmatics who received fluticasone and salmeterol but not montelukast therapy developed the same syndrome with tapering doses of oral or high doses of inhaled corticosteroids. Conclusions: The occurrence of Churg-Strauss syndrome in asthmatic patients receiving leukotriene modifiers appears to be related to unmasking of an underlying vasculitic syndrome that is initially clinically recognized as moderate to severe asthma and treated with corticosteroids. Montelukast does not appear to directly cause the syndrome in these patients.

Original languageEnglish (US)
Pages (from-to)708-713
Number of pages6
JournalChest
Volume117
Issue number3
StatePublished - 2000

Fingerprint

montelukast
Churg-Strauss Syndrome
Asthma
Adrenal Cortex Hormones
Therapeutics
Leukotriene Antagonists
Leukotrienes
Belgium
Molecular Structure

Keywords

  • Asthma
  • Churg-Strauss syndrome
  • Corticosteroid
  • Leukotriene
  • Montelukast
  • Vasculitis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Wechsler, M. E., Finn, D., Gunawardena, D., Westlake, R., Barker, A., Haranath, S. P., ... Drazen, J. M. (2000). Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest, 117(3), 708-713.

Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. / Wechsler, Michael E.; Finn, David; Gunawardena, Dineli; Westlake, Robert; Barker, Alan; Haranath, Sai P.; Pauwels, Romain A.; Kips, Johan C.; Drazen, Jeffrey M.

In: Chest, Vol. 117, No. 3, 2000, p. 708-713.

Research output: Contribution to journalArticle

Wechsler, ME, Finn, D, Gunawardena, D, Westlake, R, Barker, A, Haranath, SP, Pauwels, RA, Kips, JC & Drazen, JM 2000, 'Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma', Chest, vol. 117, no. 3, pp. 708-713.
Wechsler ME, Finn D, Gunawardena D, Westlake R, Barker A, Haranath SP et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000;117(3):708-713.
Wechsler, Michael E. ; Finn, David ; Gunawardena, Dineli ; Westlake, Robert ; Barker, Alan ; Haranath, Sai P. ; Pauwels, Romain A. ; Kips, Johan C. ; Drazen, Jeffrey M. / Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. In: Chest. 2000 ; Vol. 117, No. 3. pp. 708-713.
@article{237c0b2ad2d54604b6de53c2790c8a40,
title = "Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma",
abstract = "Study objectives: We previously reported eight patients who developed Churg-Strauss syndrome in association with zafirlukast treatment for asthma and postulated that the syndrome resulted from unmasking of a previously existing condition due to corticosteroid withdrawal and not from a direct drug effect. The availability of montelukast, a new leukotriene receptor antagonist with a different molecular structure, permitted us to test this hypothesis. Our goals were to ascertain whether the Churg-Strauss syndrome developed in patients taking montelukast and other novel asthma medications, and to describe potential mechanisms for the syndrome. Design: Case series. Setting: Outpatient and hospital practices of pulmonologists in the United States and Belgium. Patients: Four adults (one man, three women) who received montelukast as treatment for asthma; two women who received salmeterol/fluticasone therapy, but not montelukast. Results: Churg-Strauss syndrome developed in the four asthmatic patients who received montelukast. In each case, there was a long history of difficult-to-control asthma characterized by multiple exacerbations that had required frequent courses of oral systemic corticosteroids or high doses of inhaled corticosteroids for control. Two other asthmatics who received fluticasone and salmeterol but not montelukast therapy developed the same syndrome with tapering doses of oral or high doses of inhaled corticosteroids. Conclusions: The occurrence of Churg-Strauss syndrome in asthmatic patients receiving leukotriene modifiers appears to be related to unmasking of an underlying vasculitic syndrome that is initially clinically recognized as moderate to severe asthma and treated with corticosteroids. Montelukast does not appear to directly cause the syndrome in these patients.",
keywords = "Asthma, Churg-Strauss syndrome, Corticosteroid, Leukotriene, Montelukast, Vasculitis",
author = "Wechsler, {Michael E.} and David Finn and Dineli Gunawardena and Robert Westlake and Alan Barker and Haranath, {Sai P.} and Pauwels, {Romain A.} and Kips, {Johan C.} and Drazen, {Jeffrey M.}",
year = "2000",
language = "English (US)",
volume = "117",
pages = "708--713",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma

AU - Wechsler, Michael E.

AU - Finn, David

AU - Gunawardena, Dineli

AU - Westlake, Robert

AU - Barker, Alan

AU - Haranath, Sai P.

AU - Pauwels, Romain A.

AU - Kips, Johan C.

AU - Drazen, Jeffrey M.

PY - 2000

Y1 - 2000

N2 - Study objectives: We previously reported eight patients who developed Churg-Strauss syndrome in association with zafirlukast treatment for asthma and postulated that the syndrome resulted from unmasking of a previously existing condition due to corticosteroid withdrawal and not from a direct drug effect. The availability of montelukast, a new leukotriene receptor antagonist with a different molecular structure, permitted us to test this hypothesis. Our goals were to ascertain whether the Churg-Strauss syndrome developed in patients taking montelukast and other novel asthma medications, and to describe potential mechanisms for the syndrome. Design: Case series. Setting: Outpatient and hospital practices of pulmonologists in the United States and Belgium. Patients: Four adults (one man, three women) who received montelukast as treatment for asthma; two women who received salmeterol/fluticasone therapy, but not montelukast. Results: Churg-Strauss syndrome developed in the four asthmatic patients who received montelukast. In each case, there was a long history of difficult-to-control asthma characterized by multiple exacerbations that had required frequent courses of oral systemic corticosteroids or high doses of inhaled corticosteroids for control. Two other asthmatics who received fluticasone and salmeterol but not montelukast therapy developed the same syndrome with tapering doses of oral or high doses of inhaled corticosteroids. Conclusions: The occurrence of Churg-Strauss syndrome in asthmatic patients receiving leukotriene modifiers appears to be related to unmasking of an underlying vasculitic syndrome that is initially clinically recognized as moderate to severe asthma and treated with corticosteroids. Montelukast does not appear to directly cause the syndrome in these patients.

AB - Study objectives: We previously reported eight patients who developed Churg-Strauss syndrome in association with zafirlukast treatment for asthma and postulated that the syndrome resulted from unmasking of a previously existing condition due to corticosteroid withdrawal and not from a direct drug effect. The availability of montelukast, a new leukotriene receptor antagonist with a different molecular structure, permitted us to test this hypothesis. Our goals were to ascertain whether the Churg-Strauss syndrome developed in patients taking montelukast and other novel asthma medications, and to describe potential mechanisms for the syndrome. Design: Case series. Setting: Outpatient and hospital practices of pulmonologists in the United States and Belgium. Patients: Four adults (one man, three women) who received montelukast as treatment for asthma; two women who received salmeterol/fluticasone therapy, but not montelukast. Results: Churg-Strauss syndrome developed in the four asthmatic patients who received montelukast. In each case, there was a long history of difficult-to-control asthma characterized by multiple exacerbations that had required frequent courses of oral systemic corticosteroids or high doses of inhaled corticosteroids for control. Two other asthmatics who received fluticasone and salmeterol but not montelukast therapy developed the same syndrome with tapering doses of oral or high doses of inhaled corticosteroids. Conclusions: The occurrence of Churg-Strauss syndrome in asthmatic patients receiving leukotriene modifiers appears to be related to unmasking of an underlying vasculitic syndrome that is initially clinically recognized as moderate to severe asthma and treated with corticosteroids. Montelukast does not appear to directly cause the syndrome in these patients.

KW - Asthma

KW - Churg-Strauss syndrome

KW - Corticosteroid

KW - Leukotriene

KW - Montelukast

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=0034100944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034100944&partnerID=8YFLogxK

M3 - Article

C2 - 10712995

AN - SCOPUS:0034100944

VL - 117

SP - 708

EP - 713

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -